ReviewOncology and therapy2018
Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment.
Review in Oncology and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- The Promise of Chemotherapy-Free Strategies in Advanced Driver-Negative NSCLC: A Systematic Review and Network Meta-Analysis of Antiangiogenic Combination Therapies.Cancer medicine · 2026Pooled it
- Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing.Molecular cancer · 2026Trial
- Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer.World journal of gastrointestinal oncology · 2025Trial
- IDAP: an integrated literature- and knowledge-graph-driven evidence prioritization pipeline for precision oncology.Bioinformatics (Oxford, England) · 2026Article
- Obstructive sleep apnea and lung cancer: molecular underpinnings and clinical translational prospects.Frontiers in cell and developmental biology · 2026Review
- Cardiac Angiosarcoma With Lung Metastasis Presenting as Granuloma-Like Lesions: One Case Report and Literature Review.Respirology case reports · 2025Article
- The Efficacy and Safety of Endostatin Combined with Definitive Chemoradiotherapy for Unresectable Esophageal Squamous Cell Carcinoma: A Retrospective Analysis.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Article
- Efficacy analysis of endostar combined with chemoradiotherapy and immune checkpoint inhibitors in locally advanced non-small cell lung cancer.Discover oncology · 2025Article
- A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study.Discover oncology · 2025Article
- Structural Insights into Endostatin-Heparan Sulfate Interactions Using Modeling Approaches.Molecules (Basel, Switzerland) · 2024Article
- The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.Investigational new drugs · 2024Article
- Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies.Frontiers in oncology · 2024Review
- Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.Medical oncology (Northwood, London, England) · 2023Review
- Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer.Journal of clinical medicine · 2023Article
- Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Weaving the nest: extracellular matrix roles in pre-metastatic niche formation.Frontiers in oncology · 2023Review
- Combination Therapy in Cancer: Doxorubicin in Combination with an N-terminal Peptide of Endostatin Suppresses Angiogenesis and Stimulates Apoptosis in the Breast Cancer.International journal of molecular and cellular medicine · 2023Article
- Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in lung squamous cell carcinoma patients underwent conventional chemoradiotherapy.Open medicine (Warsaw, Poland) · 2023Article
- Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study.Journal of thoracic disease · 2022Article
- Anti-Angiogenic Therapy inInternational journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis plays fundamentally critical roles in solid-tumor pathogenesis, growth, invasion and metastasis. Endostatin, one of the most potent anti-angiogenic factors, was first isolated in Folkman's lab in 1997, and was reported to dramatically shrink tumor blood formation. But its insoluble and unstable nature coupled with the high cost of synthesizing the endostatin protein doomed it for clinical cancer treatment. Intrigued by Folkman's pioneering discoveries, Chinese scientists found a way to refold the protein, making it cost-effective to manufacture a recombinant human endostatin, a soluble and stable form of endostatin. A number of clinical studies have demonstrated the significant survival benefit of rh-endostatin in treating late stage non-small-cell lung carcinoma (NSCLC) and, as a result, rh-endostatin (Endostar
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.